A coalition of health care providers, insurers, seniors and others is pushing back on some of the latest claims by the Pharmaceutical Research and Manufacturers of America that incorrectly blame hospitals for the rising price of drugs. The latest installment of the Campaign for Sustainable Rx Pricing’s “Second Opinion” series highlights how hospitals are subject to fixed reimbursements for the vast majority of care they provide, and the “true driver behind the rising costs is PhRMA’s willingness to do anything for an extra dollar, even if it means forcing patients to choose between paying for the medicines they need and their daily life necessities.” CSRxP, of which the AHA is a founding member, said it will continue to fact check PhRMA’s false claims and move forward with patient-focused solutions to increase transparency, promote competition and ensure a drug’s price is based on how well it works for patients. 
 

Related News Articles

Headline
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers…
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…
Headline
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.…
Headline
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts. The plan includes…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…